Introduction {#Sec1}
============

Astrocytes are the most abundant glial cell type in the mammalian brain and play important roles in all aspects of the developing and mature organ (He and Sun [@CR14]). This includes, but is not restricted to a housekeeping function in support of neurons, the establishment and maintenance of the blood-brain barrier and the regulation of synaptogenesis and synaptic plasticity. It is perhaps not surprising then, that astrocytes are proposed to be at the root of numerous pathological processes such as glial scarring following brain injuries, Alexander disease and the most common primary brain tumor, glioma (He and Sun [@CR14]). The availability of the appropriate molecular tools to manipulate gene expression in vivo is therefore critical to further our understanding of astrocyte contributions to normal and disease states.

A large number of brain-specific bacteriophage P1 Cre recombinase-expressing mouse strains have been developed, including those using the glial fibrillary acidic protein (*GFAP*) promoter to drive astrocyte-specific expression of cre (Gaveriaux-Ruff and Kieffer [@CR12]). The expression pattern directed by the *GFAP* promoter in transgenic mice has been extensively studied and mapped (Brenner and Messing [@CR3]; Johnson et al. [@CR17]). In adult mice its activity is restricted predominantly to astrocytes while embryonic expression targets neural precursor cells of the ventricular zone and spinal cord. In addition, a subset of Gfap-expressing glial cells located in the subventricular zone of the adult brain have been shown to function as adult neural stem cells capable of giving rise to the major cell types in the brain: mature astrocytes, oligodendrocytes and neurons (Doetsch [@CR7]). Because Cre-mediated recombination is irreversible, embryonic expression in neural precursor cells directed by the *GFAP* promoter and/or aberrant expression resulting from transgene insertion effects have resulted in substantial Cre-mediated recombination in mature neurons as well as glial cells in all *GFAP-cre* mice characterized to date (Bajenaru et al. [@CR1]; Casper and McCarthy [@CR5]; Fraser et al. [@CR10]; Kwon et al. [@CR18]; Marino et al. [@CR19]; McCarty et al. [@CR20]; Zhuo et al. [@CR24]). Therefore, the ability to restrict Cre activity during embryogenesis could greatly mitigate neuronal Cre-mediated recombination in *GFAP*-Cre mice and allow for the study of gene function in mature astrocytes without disruption of function in neurons.

Cre activity can be regulated in a temporal fashion by engineering a fusion protein with the ligand binding domain of a steroid hormone receptor, such as the estrogen receptor (Feil et al. [@CR9]; Hayashi and McMahon [@CR13]). Furthermore, a specific point mutation within the ligand-binding domain termed ER^TM^ abolishes the binding to endogenous steroid hormones while retaining its interaction with synthetic estrogen analogs such as tamoxifen. The fusion protein, CreER^TM^, is inactive while sequestered in the cytoplasm by heat shock protein complexes. Binding of tamoxifen releases CreER^TM^ from this complex allowing ligand-dependent translocation to the nucleus where the fusion protein is active and directs recombination between loxP sites (Hayashi and McMahon [@CR13]). In this report, we describe the characterization of two mouse strains expressing the CreER^TM^ fusion protein under the control of the human *GFAP* promoter.

Materials and methods {#Sec2}
=====================

Transgenic and reporter mice {#Sec3}
----------------------------

Standard subcloning techniques were used to construct the transgene placing the 2.2 Kb human *GFAP* promoter (a gift from D. Gutmann) (Brenner et al. [@CR2]) upstream of the cDNA encoding the CreER^TM^ fusion protein (provided by A. McMahon). This was followed by an internal ribosomal entry sequence (IRES) and the cDNA encoding bacterial β-galactosidase (β-gal) to facilitate detection of transgene expression. The construct was terminated by an SV40 intronic sequence and polyadenylation signal. Following pronuclear injection into fertilized FVB/NJ oocytes and implantation into foster mothers, the transgenic founder was identified by polymerase chain reaction (PCR) with primers recognizing the *Cre* sequence (5′ AGCGATCGCTGCCAGGAT 3′ and 5′ ACCAGCGTTTTCGTTCTGCC 3′). Integration of the transgene was confirmed by Southern blot using a probe recognizing the SV40 sequences. The mouse line was propagated by crossing with FVB/NJ wild-type mice. Cre activity was assessed by crossing into the *Z*/*EG* reporter mouse line (Jackson Laboratory, Bar Harbor, ME) (Novak et al. [@CR22]). Reporter positive mice were identified by PCR using primers to the *GFP* gene (5′ CCGGGGTGGTGCCCATCCTGGT 3′ and 5′ GCTCCTGGACGTAGCCTTCGGGC 3′). All experiments involving mice were carried out in compliance with the Animal Care and Use Committee at St. Jude Children's Research Hospital.

Induction of Cre activity {#Sec4}
-------------------------

Tamoxifen (Sigma, St. Louis, MO) was dissolved in corn oil (Sigma) at a concentration of 20 mg/ml at 37°C, and then filter sterilized and stored for up to 7 days at 4°C in the dark. A 27 g needle tuberculin syringe (Becton Dickinson, Franklin Lakes, NJ) was used for intraperitoneal injections at the indicated doses. An equivalent volume of sterile filtered corn oil alone was used for vehicle injections. Multiple injections in the same mouse were separated by 24 h.

Histochemistry {#Sec5}
--------------

Animals were perfused with 1× phosphate-buffered saline (PBS) followed by 2% paraformaldehyde (PFA) in PBS. Following dissection, tissues were post-fixed overnight in 2% PFA in PBS at 4°C, and then equilibrated to 25% sucrose in PBS for a further 24 h at 4°C. Tissues were subsequently embedded and cryosectioned at a thickness of 12 μm. Tissue slides were washed three times in PBS prior to staining.

For detection of β-gal activity, slides were washed in Rinse A (100 mM NaPO~4~, pH 7.3; 2 mM MgCl~2~; 5 mM EGTA) for 30 min followed by Rinse B (100 mM NaPO~4~ pH 7.3; 2 mM MgCl~2~; 0.01% sodium deoxycholate; 0.02% NP-40) for 5 min. Slides were then stained at 37°C for 3--4 days in Developing Buffer (1 mg/ml X-gal; 100 mM NaPO~4~; pH 7.3; 2 mM MgCl~2~; 0.01% sodium deoxycholate; 0.02% NP-40; 5 mM K~3~Fe(CN)~6~; 5 mM K~4~Fe(CN)~6~). After washing extensively in PBS, slides were counterstained with Nuclear Fast Red (Vector Labs, Burlingame, CA).

Immunohistochemistry and immunofluorescence {#Sec6}
-------------------------------------------

Cryosections were prepared as above. Primary antibodies used for immunodetection were against GFP (1:5000 for immunohistochemistry, 1:500 for immunofluorescence; Molecular Probes, Eugene, OR), S100β (1:200; Sigma), NeuN (1:500; Chemicon, Temecula, CA), CC-1 (1:50; Calbiochem, San Diego, CA), Gfap (1:200; Sigma) and S100 (1:500; Dako, Carpinteria, CA). Microwave antigen retrieval was performed for all antibodies except anti-GFP. For immunohistochemistry, biotinylated secondary antibodies were used in conjunction with horseradish peroxidase-conjugated streptavidin (Elite ABC, Vector Laboratories) treated with NovoRed or VIP (Fig. [5](#Fig5){ref-type="fig"}) substrate (Vector Laboratories) and counterstained with hematoxylin or methyl green (Vector Laboratories), respectively. For immunofluorescence, Alexa Fluor 488 (Molecular Probes) and cyanine 3 (Jackson Immunoresearch, West Grove, PA) conjugated secondary antibodies were employed along with Vectashield mounting media containing 4′,6-diamino-2-phenylindole (Vector Laboratories).

Quantitation {#Sec7}
------------

The percentage of astrocytes undergoing Cre-mediated recombination was determined in five *GFAP*-*CreER*^TM^*A*; *Z*/*EG* mice injected with 9 mg/40 g body weight tamoxifen daily for 5 days. Serial cryosections were stained with S100 and GFP and positively stained cells (identified by visibly stained nucleus) from equivalent surface areas in various regions of the brain were counted with the aid of the Bioquant system (Bioquant Image Analysis Corp., Nashville, TN). The average number of cells counted in each mouse for the cerebellum, cortex, hippocampus and thalamus/hypothalamus was 1260, 1430, 490, and 2500, respectively. For oligodendrocytes, CC-1 positive cells in the corpus callosum of cryosections from two brains were counted (3220 cells each) and compared to the number of double positive CC-1 and GFP staining cells in an adjacent section. The total number of subventricular zone nuclei in sections from four different animals was determined (an average of 2260 nuclei per mouse) and compared to the number of GFP positive cells in the same sections.

Results {#Sec8}
=======

The cDNA encoding the CreER^TM^ fusion protein was placed downstream of the 2.2 Kb human *GFAP* promoter (Fig. [1](#Fig1){ref-type="fig"}a) (Brenner et al. [@CR2]). This was followed by an internal ribosomal entry site (IRES) and a *LacZ* cDNA encoding a nuclear-targeted version of *E. coli* β-galactosidase (β-gal). The construct was terminated by an SV40 large T intron and polyadenylation signal. After pronuclear injection of FVB/NJ eggs, one founder was obtained. Transgene integration in this line, hereafter termed *GFAP*-*CreER*^TM^, was verified by polymerase chain reaction (PCR) for *Cre*-specific sequences as well as by Southern blot hybridization (Fig. [1](#Fig1){ref-type="fig"}b). The latter result suggested the presence of two independent integration sites, a conclusion which was supported by a frequency of *Cre*-positive F1 progeny of 76% (63 *Cre*-positive out of 83 total pups). After several rounds of breeding to wild-type FVB mice, the two integration sites were separated into independent lines (*GFAP*-*CreER*^TM^*A*; Fig. [1](#Fig1){ref-type="fig"}b, lanes 6--8, and *GFAP*-*CreER*^TM^*B*; Fig. [1](#Fig1){ref-type="fig"}b, lanes 3--5). Furthermore, a single integration site in each line was verified by fluorescence in situ hybridization (FISH) for the transgene in MEF cells generated from each *GFAP*-*CreER*^TM^ mouse line with chromosomal location of 9A5 for line A and 15E3 for line B (data not shown).Fig. 1Generation of transgenic mouse lines. (**a**) Diagram of transgenic construct. The 2.2 Kb human *GFAP* promoter drives expression of cDNAs encoding the Cre-estrogen receptor ligand binding domain (CreER^TM^) fusion protein, an internal ribosome entry site (IRES) and *E. coli* β-galactosidase (β-gal). (**b**) Southern blot. Genomic DNAs from the transgenic founder mouse and a panel of F1 progeny were digested with *Eco*RI (location of restriction sites within the transgene are indicated in panel (**a**)) to detect fragments resulting from internal digest of the multicopy transgene as well as those containing the junction of the transgene with the insertion sites in genomic DNA. The fragments corresponding to the insertion site for *GFAP*-*CreER*^TM^*A* (arrowhead) and for *GFAP*-*CreER*^TM^*B* (arrow) are shown. The probe was directed against SV40 sequences as indicated in panel (**a**)

Transgene expression was characterized by histochemistry for β-gal activity in adult mouse brains. In wild-type mice, occasional histochemical staining was noted in cells of the pial membranes, representing endogenous β-gal activity (data not shown) (Chow et al. [@CR6]). In contrast, *GFAP*-*CreER*^TM^ brains exhibited specific and reproducible patterns of β-gal activity that were virtually identical between the two mouse lines. Cells expressing β-gal were scattered throughout all regions of the brain (Fig. [2](#Fig2){ref-type="fig"}a, f), however, the specific pattern in certain areas was notable. In the cerebellum, many β-gal positive cell bodies aligned along the Purkinje cell layer with cellular processes extending into the molecular layer (Fig. [2](#Fig2){ref-type="fig"}b, c arrows, g, h, arrows), a morphological feature consistent with Bergmann glia. In the dentate gyrus, β-gal positive cells tended to cluster in the inner layer of this structure (Fig. [2](#Fig2){ref-type="fig"}d, i arrows) where neural precursor cells are known to reside (Doetsch [@CR7]). Histochemical staining for β-gal activity was also noted in cells of the subventricular zone surrounding the lateral ventricle (Fig. [2](#Fig2){ref-type="fig"}e, j arrows) where Gfap-expressing adult neural stem cells have also been identified (Doetsch [@CR7]). No β-gal activity was detected in a panel of tissues from *GFAP*-*CreER*^TM^ adult mice including muscle, skin, lung, thymus, heart, liver, spleen, adrenal gland, pancreas, bladder, uterus, ovary and epididymus (data not shown). β-gal activity was detected in the gastrointestinal tract, kidney and testis however this likely represents endogenous activity as similar staining was also noted in non-transgenic control animals (data not shown).Fig. 2Transgene expression analysis of adult *GFAP*-*CreER*^TM^ brains by β-gal histochemistry. (**a**--**e**) *GFAP*-*CreER*^TM^*A* brain. (**f**--**j**) *GFAP*-*CreER*^TM^*B* brain. (**a**, **f**) Sagittal sections of brain. Scale bar in (**a**) is 1 mm and applies to (**f**). (**b**, **c**, **g**, **h**) Sagittal sections of cerebellum at low (**b**, **g**) and high (**c**, **h**) power. The arrows in (**c**) and (**h**) indicate the location of Bergman glia. Scale bar in (**b**) is 0.5 mm and applies to (**g**) and that in (**c**) is 50 μm and applies to (**h**). (**d**, **i**) Sagittal sections through dentate gyrus. The arrows indicate the inner layer of the dentate gyrus, the location of neural progenitor cells. Scale bar in (**d**) is 100 μm and applies to (**i**). (**e**, **j**) Sagittal sections through subventricular zone. The arrows indicate a transgene-expressing cell in the subventricular zone. Scale bar in (**e**) is 10 μm and applies to (**j**)

Reporter mice were used to assess the activity of the CreER^TM^ fusion protein following treatment with tamoxifen or vehicle. *GFAP*-*CreER*^TM^ mice were crossed with *Z*/*EG* reporter mice in which the cDNA encoding enhanced green fluorescent protein (GFP) is expressed only after Cre-mediated excision of a *LoxP*-flanked stop cassette (Novak et al. [@CR22]). Mice were injected starting at 40--50 days of age intraperitoneally with tamoxifen at a dose of 9 mg/40 g body weight or vehicle alone daily for five injections, then sacrificed at least 5 days after the last injection and tissues analyzed by immunohistochemistry for GFP. In single transgenic mice (either *GFAP*-*CreER*^TM^ or *Z*/*EG* alone), no GFP immunoreactivity was detected in the brain (Fig. [3](#Fig3){ref-type="fig"}a--c and data not shown). In double transgenic mice injected with vehicle, occasional GFP positive cells were present, particularly in cerebellar Bergmann glia (Figs. [3](#Fig3){ref-type="fig"}d--f and [5](#Fig5){ref-type="fig"}a--c). This tamoxifen-independent Cre-mediated recombination accumulated slowly over the period of 14 months remaining predominantly localized to Bergmann glial cells (Fig. [3](#Fig3){ref-type="fig"}d, e insets) and represents the "leakiness" of this inducible Cre strain. In contrast, tamoxifen-injected mice displayed widespread GFP expression mirroring the pattern of β-gal activity in *GFAP*-*CreER*^TM^ single transgenic mice (Figs. [3](#Fig3){ref-type="fig"}g--i and [5](#Fig5){ref-type="fig"}d--f). Under higher magnification, the cortical staining pattern for GFP revealed cells exhibiting a stellate morphology consistent with mature astrocytes (Figs. [4](#Fig4){ref-type="fig"}a and [5](#Fig5){ref-type="fig"}g). Furthermore, GFP-expressing cells were detected in the inner layer of the dentate gyrus (Figs. [4](#Fig4){ref-type="fig"}b and [5](#Fig5){ref-type="fig"}h arrows) and in the subventricular zone (Figs. [4](#Fig4){ref-type="fig"}c and [5](#Fig5){ref-type="fig"}i) consistent with β-gal activity (Fig. [2](#Fig2){ref-type="fig"}d, e, i, j). GFP-expressing cells were also noted in the corpus callosum (Figs. [4](#Fig4){ref-type="fig"}d and [5](#Fig5){ref-type="fig"}j).Fig. 3Cre-mediated recombination in adult brains by immunohistochemistry for GFP reporter. (**a**--**c**) *Z*/*EG* single transgenic mouse injected with 9 mg/40 g tamoxifen daily for 5 days. (**d**--**f**) *GFAP*-*CreER*^TM^*A*; *Z*/*EG* double transgenice mouse injected with vehicle daily for 5 days. Inset represents images from an uninduced 14-month-old double transgenic mouse whereas all other mice presented are \~8 weeks of age as indicated in the text. (**g**--**i**) *GFAP*-*CreER*^TM^*A*; *Z*/*EG* double transgenic mouse injected with 9 mg/40 g tamoxifen daily for 5 days. Brain regions presented are sagittal sections through the cerebellum (panels **a**, **d**, **g**), cerebral cortex and hippocampus (panels **b**, **e**, **h**) and thalamus and hypothalamus (panels **c**, **f**, **i**). Scale bar is 0.5 mm and applies to all panelsFig. 4Cre-mediated recombination in adult *GFAP*-*CreER*^TM^*A*; *Z*/*EG* brains by immunohistochemistry for GFP. Mice were treated with tamoxifen as in Fig. [3](#Fig3){ref-type="fig"}. (**a**) Cerebral cortex. The stellate appearance of a cortical GFP-stained cell resembling an astrocyte is presented. (**b**) Dentate gyrus. The arrow indicates a GFP-stained cell located in the inner layer of the dentate gyrus which may represent a neural precursor cell. (**c**) Subventricular zone. These GFP-positive cells may represent self-renewing B cells of the subventricular zone. (**d**) Corpus callosum. Scale bar in (**a**) is 10 μm and applies to panels (**a**, **c**, **d**). Scale bar in (**b**) is 50 μmFig. 5Cre-mediated recombination in adult *GFAP*-*CreER*^TM^*B*; *Z*/*EG* brains by immunohistochemistry for GFP. Mice were treated with tamoxifen as in Fig. [3](#Fig3){ref-type="fig"}. (**a**--**c**) *GFAP*-*CreER*^TM^*B*; *Z*/*EG* double transgenice mouse injected with vehicle daily for 5 days. (**d**--**f**) *GFAP*-*CreER*^TM^*B*; *Z*/*EG* double transgenic mouse injected with 9 mg/40 g tamoxifen daily for 5 days. Brain regions presented are sagittal sections through the cerebellum (panels **a**, **d**), cerebral cortex and hippocampus (panels **b**, **e**) and thalamus and hypothalamus (panels **c**, **f**). Scale bar in (**a**) is 0.5 mm and applies to panels (**a**--**f**). (**g**) High power image of GFP-positive cell in the cerebral cortex. (**h**) Dentate gyrus. The arrow indicates a GFP-stained cell located in the inner layer of the dentate gyrus. (**i**) Subventricular zone. (**j**) Corpus callosum. Scale bar in (**g**) is 10 μm and applies to panels (**g**, **i**, **j**). Scale bar in (**h**) is 50 μm

To confirm the cell types targeted for Cre activity, double labeling by immunofluorescence was performed. The majority of GFP-labeled cells in all regions of the brain were found to co-express S100β, a marker for glial cells (Fig. [6](#Fig6){ref-type="fig"}a--c). In contrast, almost no GFP-labeled cells co-expressed NeuN, a marker of mature neurons (Fig. [6](#Fig6){ref-type="fig"}d--f), although the occasional double-labeled granule neuron in the dentate gyrus, was noted (Fig. [6](#Fig6){ref-type="fig"}f arrow). It is possible that such cells were Gfap-expressing neural precursors when tamoxifen was administered, then subsequently differentiated into granule neurons during the 5--10-day-period prior to analysis. Alternatively, this transgenic line may drive CreER expression in the rare mature granule neuron. However, immunophenotypical analyses of multiple *GFAP*-*CreER*^TM^ single transgenic mice failed to identify any CreER expression in neurons (data not shown). GFP-expressing oligodendrocytes in the corpus callosum were identified by co-expression of the CC-1 antigen (Fig. [6](#Fig6){ref-type="fig"}g). Confocal microscopy was used to confirm Cre activity in occasional Gfap positive neural precursor cells of the subventricular zone (Fig. [7](#Fig7){ref-type="fig"}).Fig. 6Identification of cells undergoing Cre-mediated recombination in adult *GFAP*-*CreER*^TM^*A*; *Z*/*EG* brains by double immunofluorescence. Mice were treated with tamoxifen as in Fig. [3](#Fig3){ref-type="fig"}. (**a**--**c**) Staining with an astrocyte marker and anti-GFP. Co-immunodetection of S100β (green) and GFP (red) is demonstrated in the cerebellum (**a**), cerebral cortex (**b**) and dentate gyrus (**c**). (**d**--**f**) Staining with a neuronal marker and anti-GFP. There is no co-immunodetection of NeuN (green) and GFP (red) in cerebellum (**d**) and cortex (**e**) while occasional granule neurons of the dentate gyrus (**f**) express both markers (arrow). (**g**) Staining with an oligodendrocyte marker and anti-GFP. Cells staining with both CC-1 (green) and GFP (red) were readily identified in the corpus callosum. Scale bar in (**f**) is 50 μm and applies to panels (**a**--**f**). Scale bar in (**g**) is 20 μm. DAPI: 4′,6-diamino-2-phenylindole (blue). Immunophenotyping results were identical in the *GFAP*-*CreER*^TM^*B* line (data not shown)Fig. 7Confocal imaging of subventricular zone in adult *GFAP*-*CreER*^TM^*A*; *Z*/*EG* brains. Mice were treated with tamoxifen as in Fig. [3](#Fig3){ref-type="fig"}. (**a**, **b**) Staining with antibodies against Gfap (green) and GFP (red) with DAPI (blue). Occasional cells co-expressing these two markers in the subventricular zone were identified in these 1 μm optical sections. Scale bar in (**a**) is 10 μm and applies to both panels

The degree of Cre-mediated recombination was assessed by examining sections serially stained for S100 and GFP proteins in various regions of the brain (Table [1](#Tab1){ref-type="table"}). Overall, astrocyte recombination ranged from 35% to 70% and was more efficient in the cerebellar Bergmann glia than in other parts of the brain. Interestingly, \<1% of all cells in the subventricular zone showed cre-mediated recombination under the experimental conditions tested and probably represent Cre activity in the Gfap-expressing B cells (Fig [7](#Fig7){ref-type="fig"}) (Doetsch [@CR7]). This population has been reported to comprise 20--25% of cells in the subventricular zone (Doetsch et al. [@CR8]). Increasing the dose of tamoxifen administered did not result in further elevations in the number of GFP positive cells (data not shown), however, recombination could be restricted to fewer astrocytes by titrating the drug dose from 9 to 1 mg/40 g body weight in a single injection (Fig. [8](#Fig8){ref-type="fig"}).Fig. 8Dose--dependent regulation of Cre-mediated recombination by decreasing tamoxifen. Immunohistochemistry for GFP was performed. (**a**--**c**) *GFAP*-*CreER*^TM^*A*; *Z*/*EG* double transgenice mouse injected with a single 1 mg/40 g dose of tamoxifen. (**d**--**f**) *GFAP*-*CreER*^TM^*A*; *Z*/*EG* double transgenice mouse injected with a single 3 mg/40 g dose of tamoxifen. (**g**--**i**) *GFAP*-*CreER*^TM^*A*; *Z*/*EG* double transgenice mouse injected with a single 9 mg/40 g dose of tamoxifen. Brain regions presented are sagittal sections through the cerebellum (panels **a**, **d**, **g**), cerebral cortex (panels **b**, **e**, **h**) and hippocampus (panels **c**, **f**, **i**). Scale bar is 0.5 mm and applies to all panelsTable 1Quantitation of Cre-mediated recombination in different brain regions of *GFAP*-*CreER*^TM^*A* miceRegion% Recombination (SEM)Cerebellar astrocytes (Bergmann glia)70.8 (2.5)Cortical astrocytes52.9 (6.1)Hippocampal astrocytes44.3 (3.9)Thalamic/hypothalamic astrocytes35.1 (3.4)Corpus callosum oligodendrocytes\<1.0Subventricular zone cells\<1.0

Discussion {#Sec9}
==========

The *GFAP*-*CreER*^TM^ mouse lines described in this report represent useful tools for investigators interested in studying the effects of gene manipulation in mature astrocytes. Virtually no Cre activity is present in neurons, specifically in the cortex, allowing for the study of cell autonomous phenomena in this cell population. This may be particularly relevant to the fields of brain injury and repair as well as to gliomagenesis. Furthermore, the presence of detectable Cre activity in a subset of adult neural precursor cells in the dentate gyrus and the subventricular zone may also facilitate the study of regenerative and oncogenic potentials of this increasingly scrutinized cell population.

Recently, similar transgenic mouse lines have been reported in which the CreER^T2^ fusion protein (Indra et al. [@CR16]) was expressed under the control of the identical *GFAP* promoter (Casper et al. [@CR4]; Ganat et al. [@CR11]; Hirrlinger et al. [@CR15]). One report described CreER activity in young (five-day-old) mice and found that neural precursor cells were significantly targeted at this age (Ganat et al. [@CR11]). Interestingly, these cells went on to differentiate into mature neurons, oligodendrocytes and astrocytes in vivo taking residence in all regions of the brain. We have yet to examine CreER activity in our juvenile mice. Two other groups have documented CreER activity in adult astrocytes (Casper et al. [@CR4]; Hirrlinger et al. [@CR15]). One line appears to have broad activity in astrocytes, although quantitation was not reported (Casper et al. [@CR4]), while the other is more restricted to certain regions of the brain (Hirrlinger et al. [@CR15]). Neither group commented on CreER activity in adult neural precursor cells. Other astrocyte-specific inducible Cre mouse strains have also been described with activity in adult neural progenitor cells (Mori et al. [@CR21]; Slezak et al. [@CR23]). We describe CreER activity in a broad range of adult astrocytes as well as in a restricted population of adult neural progenitor cells. While the pattern of expression is largely similar between our two lines, the degree of CreER expression and consequently of recombination in astrocytes appears to be slightly greater in the *GFAP*-*CreER*^TM^*A* line (compare Figs. [2](#Fig2){ref-type="fig"}a--f and [3](#Fig3){ref-type="fig"}h, i to [5](#Fig5){ref-type="fig"}e, f). In addition, by using a less sensitive variant of the CreER fusion protein, we demonstrated an easily achievable dose-response effect to tamoxifen that may be advantageous for certain studies, such as cell-fate mapping and tumorigenesis. We have successfully generated spontaneous models for diffuse astrocytomas using our *GFAP*-*CreER*^TM^*A* line (L.M.L.C. and S.J.B., unpublished data). Together, these various CreER mouse lines provide novel and powerful tools for investigators to probe normal and pathological astrocyte functions.
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